Vision
At Braindoot Lifesciences, we envision a future where glioblastoma and other central nervous system (CNS) malignancies are treatable diseases, significantly improving patient survival and quality of life. We are dedicated to pioneering brain-penetrant therapies that precisely target and overcome the challenges of the blood-brain barrier.
Mission
At Braindoot Lifesciences, our mission is to transform outcomes in glioblastoma and other CNS malignancies by developing brain-penetrant therapies that precisely cross the blood-brain barrier. Through innovative, novel target inhibitors and tissue-specific targeting platforms, we aim to redefine the standards of care and improve survival and quality of life for patients facing the most challenging brain cancers.
Our Approach
Braindoot Lifesciences is at the forefront of neuro-oncology, developing innovative small-molecule therapeutics delivered via a proprietary exosome-based platform. This unique approach allows for targeted delivery to the central nervous system, minimizing systemic exposure and reducing off-target toxicity. By combining precision brain targeting with minimized toxicity, we are addressing critical unmet needs in the most challenging brain indications.
Our Platforms
Explore our cutting-edge bio-tech services for your business.
Our Team
Co-Founder
Geeta Singh
With over 20 years of experience in process development, GMP operations, technology transfer, and scaling manufacturing infrastructure for biologics and advanced therapies, I bring a unique blend of scientific expertise and operational as well as business leadership to drive innovation and efficiency in complex biomanufacturing environments.
Co-Founder
Karthika Nair
With over 10 years of experience in biotech research, operations, and clinical readiness, I lead scientific operations at Praesidia, bringing expertise across both small and large molecule programs in R&D and commercial settings. I’ve led cross-functional teams advancing early-stage therapeutics, grounded in a strong foundation in neurobiology and translational science.
Co-Founder and Chief Strategic Advisor
Pradip Majumder, PhD
With over 25 years of experience in oncology research and drug development, I am a pioneer in tumour biology and patient stratification platforms, having co-founded multiple ventures and led successful CRO and biotech exits. I have also led two oncology programs from discovery through Phase II clinical trials, driving innovation from bench to bedside. to drive innovation and efficiency in complex bio-manufacturing environments.
